Clinical trial
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
NCT00004635 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004635 |
|---|---|
| Title | Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer |
| Official title | A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Holy Cross Hospital, Fort Lauderdale Louisiana State University Health Sciences Center in New Orleans Wayne State University University of Minnesota Columbia University University of Pittsburgh United… |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | Thalidomide, leuprolide acetate, goserelin, Placebo |
| Enrollment | 159 |
| Start date | Mar 1, 2000 |
| Primary completion | Jan 30, 2005 |
| Completion | Mar 30, 2010 |
| First posted | Feb 21, 2000 |
| Last update posted | May 22, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: